Regulation
The US FDA announces in a Nov. 28 Federal Register notice that it will withdraw its proposed rule under MoCRA for testing asbestos in talc-containing products, but remains committed to meeting its statutory requirements under the law.
Congress’ reauthorization of OMUFA for five years includes measures that promote non-animal testing for sunscreen, a broadening of the evidence that can be used to support safety and additional funding for MoCRA.
Consultants urge packaging producers to forecast and budget now for the fees of state EPR programs, particularly as fees from the Oregon program hit and surprise many firms and expose gaps in internal budgeting and planning. The topic was discussed at IBA’s Cosmetics Convergence 2025 conference.
The US FDA’s decision to move its long-awaited cosmetic GMPs rule to ‘Long-Term Actions’ under MoCRA likely delays a final rule for at least five years, raising the risk of increased state regulation and private litigation, say attorneys speaking during the 2025 PCPC Science Symposium & Expo
Regulations likely holding consumer product firms’ attention include the Plastic Pollution Prevention and Packaging Producer Responsibility Act, SB 54, scheduled to become effective by 2027. “Easily the most significant, extended producer responsibility law ever to pass in the world,” says lobbyist
A Senate committee is investigating leadership changes at the US Centers for Disease Control and Prevention. While the primary focus is vaccine policy, the first hearing suggested the probe could raise questions about FDA independence.
Retailers selling beauty products in the state of Washington who plan to dispose of unpurchased products by Jan. 1 must follow the state's Dangerous Waste Reduction law, which categorizes waste generators as small, medium or large.
Continuing work includes “for cause and certain surveillance inspections of regulated facilities” and “criminal enforcement work and certain civil investigations” as White House mulls layoffs rather than furloughs during federal government shutdown.
The Washington Department of Ecology will begin collecting feedback for its rulemaking on lead limits for cosmetics under the Toxic Free Cosmetics Act early next year, and industry’s response throughout the process will be critical to determine the outcome.
Recent FDA warning letters hit typical problems in consumer health space such as manufacturing quality control deficiencies, but also note honey offered for eye infections and nasal spray to enhance cognitive function.
In separate cases in California and Europe, courts reached similar conclusions regarding the potential carcinogenicity of titanium dioxide in respirable form and its impact on regulations.
Washington regulators announce restrictions on intentionally added formaldehyde releasers take effect Jan. 1, 2027, with retailers having until Jan. 1, 2028, to sell through existing stock.
UK consumer advocacy organization finds more than two-thirds of 34 skin care and makeup products it purchased from third party sellers on major ecommerce sites are likely fake.
What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.
While FDA fully supports the recent roadmap to reduce and eliminate animal testing, animal tests are still necessary for assessing systemic effects, says Jacqueline Corrigan-Curay, acting director for CDER, during a House Energy and Commerce Health Subcommittee hearing.
The European Commission’s Simplification Omnibus published July 8 is ‘step in right direction’ for streamlining processes and providing more legal certainty and predictability for regulations addressing cosmetics, says Cosmetics Europe.
White House announces president extends deadline he set in April for other countries to make new tariff deals from July 9 to Aug. 1, when the administration will start sending letters warning other countries that higher tariffs could take effect.
ECHA has added two silicone ingredients used in cosmetics and personal care products to the REACH Candidate List as they are persistent and have bioaccumulative properties, requiring companies to notify customers and update safety data sheets if concentrations exceed 0.1%.
The delay in implementation of MoCRA is seen by many companies as a temporary reprieve, but it does create more legal uncertainty, says attorney Marissa Alkhazov of law firm Buchalter.
The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.